All In Biotech

NDA 021875 · Nuvo Pharms

Nuvigil

Armodafinil · Oral

Last checked: Nov 20, 2026Latest source record: Feb 7, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Jun 15, 2007

Approved uses

1

Original approval plus efficacy supplements

Registered trials

56

22 Phase 3, 1 recruiting

FAERS reports

21,062

9,699 serious, 326 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 24, 2026.

NUVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Limitations of Use In OSA, NUVIGIL is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating NUVIGIL for excessive sleepiness. NUVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). ( 1 ) Limitations of Use In OSA, NUVIGIL is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction.

Mechanism: The mechanism(s) through which armodafinil promotes wakefulness is unknown. Armodafinil (R-modafinil) has pharmacological properties similar to those of modafinil (a mixture of R- and S-modafinil), to the extent tested in animal and in vitro studies. The R- and S-enantiomers have similar pharmacological actions in animals. Armodafinil and modafinil have wake-promoting actions similar to sympathomimetic agents including amphetamine and methylphenidate, although their pharmacologic profile is not identical to that of the sympathomimetic amines. Modafinil-induced wakefulness can be attenuated by...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • NUVIGIL · ARMODAFINIL 150MG · TABLET, ORAL · Prescription · TE AB
  • NUVIGIL · ARMODAFINIL 50MG · TABLET, ORAL · Prescription · TE AB
  • NUVIGIL · ARMODAFINIL 250MG · TABLET, ORAL · Prescription · TE AB
  • NUVIGIL · ARMODAFINIL 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • NUVIGIL · ARMODAFINIL 200MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Armodafinil" as an intervention, any sponsor and status, largest first.

All 56 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,579
  • fatigue1,525
  • nausea1,487
  • headache1,411
  • anxiety1,187
  • somnolence1,110
  • depression1,021
  • insomnia986
  • feeling abnormal961
  • fall897
  • dizziness880
  • weight decreased748

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20084
200959
2010202
2011445
20122,692
2013763
2014820
20152,028
20165,261
20171,670
20181,525
20191,432
20201,044
2021540
2022622
2023681
2024612
2025399
2026263

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nuvigil (Armodafinil)

2024 spending

$3.5M

Beneficiaries

386

2,320 claims

Per beneficiary

$9,047

$34.26 per unit

View as table
YearSpending
2020$5,887,531
2021$4,764,572
2022$4,663,639
2023$3,760,951
2024$3,492,163

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 91 on PubMed

Sponsor: Nuvo Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.